HARCP

HEROIN ADDICTION AND
RELATED CLINICAL PROBLEMS

The official journal of
EUROPAD - European Opiate Addiction Treatment Association
WFTOD - World Federation for the Treatment of Opioid Dependence
Editor: Icro Maremmani, MD - Pisa, Italy, EU
Associate Editors:
Thomas Clausen, MD - Oslo, Norway
Pier Paolo Pani, MD - Cagliari, Italy, EU
Marta Torrens, MD - Barcelona, Spain, EU
Statistical Editor:
Mario Miccoli, PhD - Pisa, Italy, EU

HARCP Archives

Browse by article Browse by volume    

Heroin Addiction and Related Clinical Problems: 2003, 05, 1 (pages: 5 - 16)

The impact of methadone substitution therapy (MST) on illicit drug use and drug abused-related quality of life: A European Study

Ghodse H., Clancy C., Oyefeso A., Rosinger C., Finkbeiner T., Schifano F., Forza G., Sommer B., Nielson K. R., Schodt J., Wieviorka S., Gionnet C., O'connor J., Tidone L., Riglietta M., Lopes I., Torrens M., San L., Montes M., Copez C. R.

Summary: commonly used treatments for opiate dependence, legitimate questions continue to be raised about its effectiveness. Objective: To evaluate the impact of MST on illicit drug use and drug abuse-related quality of life (QoL). Design: Multicentre, cross-sectional case control study. Setting: Eleven MST programmes in eight European countries. Participants: Heroin dependent patients in MST programmes. Main outcome measures: Data on illicit drug use in the last month and injecting behaviour was extracted from the patientʼs substance use profile derived from EuroSUD as part of intake and ongoing assessment. The Brief Addiction Recovery Status Scale (EuroSAAQ-BARSS). Results: In Treatment (IT) groups reported a significantly lower number of illicit drugs used in the last month than controls (IT1: t = -6.81, p <.00001; IT2: t = -7.61, p <.00001; IT3: t = -6.32, p <.00001; IT4: t = -10.14, p <.00001). IT patients reported significantly lower rates of injecting than controls IT1 (OR = 0.48, 95%CI = 0.24, 0.95), IT2 (OR = 0.21, 95%CI = 0.12, 0.37), IT3 (OR = 0.43, 95%CI = 0.22, 0.87) and IT4 (OR = 0.27, 95%CI = 0.13, 0.57). They also expressed better drug-abuse related QoL for those patients who had been in treatment for at least 7 months (IT2: t = 4.43, p <.00001; IT3: t = 4.52, p <.00001; IT4: t = 6.22, p <.00001). Furthermore, there was a consistently positive relationship between duration in treatment and QoL scores. Conclusions: MST impacts positively on illicit drug use, injecting and drug abuse-related QoL. MST has been demonstrated as a culture-free and

 

AU-CNS Associazione per l’Utilizzo delle Conoscenze Neuroscientifiche a fini Sociali
Association for the Application of Neuroscientific Knowledge to Social Aims
Via XX Settembre, 83 – 55045 PIETRASANTA (Lucca) - Italy
P. IVA 01681650469 – Codice Fiscale 94002580465 Reserved Area
Tel/Phone: 0584 - 790073 - Email: info@heroinaddictionrelatedclinicalproblems.org
Start of page